One core capability at GenMark is our comprehensive and rigorous quality and regulatory processes that are designed specifically to support IVD tests. A number of other tests, including HCV Genotyping and 2C19, versions of which are available for research use only, are in development for IVD use. A Respiratory Viral Panel (RVP) has been submitted to the FDA for 510(k) clearance. GenMark currently markets three tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, and Thrombophilia Risk Test. GenMark multiplex molecular diagnostic tests are FDA-cleared. Married with two children enjoys family activities including traveling participates in several sports including running and cycling. President and Chief Executive Officer and member of the Board of Directors at GenMark Diagnostics since April 2011 prior to that, served as President of Ventana Medical Systems and Head of Roche Tissue Diagnostics held various global leadership positions with Ventana, Bayer Diagnostics, and Chiron Diagnostics.īS in Microbiology and Immunology from Monash University, Australia MBA from Melbourne University, Australia. The system provides automated result interpretation and requires no calibration or routine maintenance. The value to our customers is testing that involves minimal hands-on time. By comparison, eSensor can accurately detect up to 72 targets on the same test cartridge.įurthermore, our technology does not require lasers, cameras, or washing, so our system is very simple, with no moving parts or any waste generated. Fluorescence, chemi-luminescence, and other “optical-based” detection systems have very limited multiplexing capabilities. GenMark’s eSensor technology does not suffer from interferences that impact other detection technologies. Our proprietary electrochemical detection technology and innovative XT-8 System provide our customers with accurate, standardized assays that improve the efficiency of the laboratory. The eSensor XT-8 System represents an advance in technology during an era of increasing growth in molecular diagnostics. Our expertise is in the design, development, and commercialization of molecular systems and assays based on our proprietary electrochemical detection technology called eSensor®.
We provide high medical value, easy to perform tests that improve patients’ lives. GenMark’s vision is to be a leader in multiplex molecular diagnostics.
0 kommentar(er)
